Loading...
Market
What will be the percentage increase in Roche's share price one year after the CT-388 trial announcement?
3
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Stock market data
Story
Roche's CT-388 Shows 18.8% Weight Loss in Phase I Trial at 24 Weeks
May 16, 2024, 06:25 AM
Roche has reported positive Phase I results for its dual GLP-1/GIP receptor agonist, CT-388, in people with obesity. The drug demonstrated an 18.8% placebo-adjusted weight loss at 24 weeks, which is faster than the results seen with Wegovy. This promising data comes from a trial size of 96 participants and is part of Roche's $3.1 billion acquisition of Carmot Therapeutics. The news has already impacted Roche's shares positively, with shares trading up.
View original story
Similar markets
Outperforms • 25%
Underperforms • 25%
Matches • 25%
Data Inconclusive • 25%
Decrease more than 10% • 25%
Decrease less than 10% • 25%
Increase less than 10% • 25%
Increase more than 10% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
High Adoption • 33%
Moderate Adoption • 33%
Low Adoption • 34%
Increase by > 20% • 25%
Increase by 10-20% • 25%
Increase by < 10% • 25%
No significant change or decrease • 25%
Below 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
Above 50% • 25%
Less than 10% • 25%
Between 10% and 50% • 25%
Between 50% and 100% • 25%
More than 100% • 25%
Decrease by more than 10% • 33%
No significant change • 33%
Increase by more than 10% • 33%
Increase by more than 20% • 33%
Increase by 0-20% • 33%
Decrease • 33%